• Knight Therapeutics’ management commentary attributed third-quarter 2026 revenue growth of 13% to promoted products and stronger Latin American currencies.
• Revenue reached CAD 137.69 million; customer purchasing patterns partially offset growth, leaving constant-currency adjusted revenue up 4%.
• Operating loss totaled CAD 6.55 million, reflecting a CAD 12.09 million contingent consideration remeasurement charge tied to higher expected sales milestones.
• Adjusted EBITDA rose 13% to CAD 23.8 million as higher adjusted gross profit outweighed increased operating expenses.
• Net loss narrowed to CAD 2.68 million from CAD 3.79 million, supported by investment gains and a tax recovery.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Knight Therapeutics Inc. published the original content used to generate this news brief on November 12, 2026, and is solely responsible for the information contained therein.